Cargando…

The human CD40 agonistic antibody ADC-1013 generates immune mediated anti-tumor effects in syngeneic tumor models in hCD40 transgenic mice

Detalles Bibliográficos
Autores principales:	Mangsbo, Sara M, Veitonmäki, Niina, Gustfson, Erika, Smith, Karin Enell, Furebring, Christina, Norlén, Per, Lindstedt, Malin, Tötterman, Thomas H, Ellmark, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292546/ http://dx.doi.org/10.1186/2051-1426-2-S3-P251

Ejemplares similares

Pre-clinical development of the human CD40 agonistic antibody ADC-1013
por: Norlén, Per, et al.
Publicado: (2015)

ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer
por: Mangsbo, Sara M, et al.
Publicado: (2013)

Kick-starting the cancer-immunity cycle by targeting CD40
por: Ellmark, P, et al.
Publicado: (2015)

Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation
por: Ellmark, Peter, et al.
Publicado: (2016)

The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo
por: Deronic, Adnan, et al.
Publicado: (2021)

The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
por: Kvarnhammar, Anne Månsson, et al.
Publicado: (2019)

Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer
por: Sandin, Linda C, et al.
Publicado: (2014)

Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody
por: Andersson, Hampus, et al.
Publicado: (2023)

Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients
por: Schiza, A., et al.
Publicado: (2017)

Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients
por: Loskog, Angelica, et al.
Publicado: (2016)

Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy
por: Georganaki, Maria, et al.
Publicado: (2020)

Selective Elimination of a Chemoresistant Side-Population of B-CLL Cells by Cytotoxic T Lymphocytes in Subjects Receiving an Autologous hCD40L/IL-2 Tumor Vaccine
por: Foster, Aaron E, et al.
Publicado: (2010)

Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
por: Hägerbrand, Karin, et al.
Publicado: (2022)

CD40–CD40L in Neurological Disease
por: Ots, Heather D., et al.
Publicado: (2022)

Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients
por: Irenaeus, Sandra, et al.
Publicado: (2017)

MYC inhibition reprograms tumor immune microenvironment by recruiting T lymphocytes and activating the CD40/CD40L system in osteosarcoma
por: Jiang, Kuo, et al.
Publicado: (2022)

Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment
por: Eriksson, E, et al.
Publicado: (2017)

Triggering CD40 on endothelial cells contributes to tumor growth
por: Chiodoni, Claudia, et al.
Publicado: (2006)

Adipocytes in their (CD)40s
por: Bertola, Adeline, et al.
Publicado: (2023)

CD40-CD40L Interaction in Immunity Against Protozoan Infections
por: Chamekh, Mustapha
Publicado: (2007)

The Role of CD40/CD40 Ligand Interactions in Bone Marrow Granulopoiesis
por: Mavroudi, Irene, et al.
Publicado: (2011)

CD40/CD40 LIGAND INTERACTIONS IN IMMUNE RESPONSES AND PULMONARY IMMUNITY
por: KAWABE, TSUTOMU, et al.
Publicado: (2011)

The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease
por: Bosmans, Laura A., et al.
Publicado: (2020)

Platelets as Key Factors in Inflammation: Focus on CD40L/CD40
por: Cognasse, Fabrice, et al.
Publicado: (2022)

Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors
por: Wongthida, Phonphimon, et al.
Publicado: (2020)

Levels of human platelet-derived soluble CD40 ligand depend on haplotypes of CD40LG-CD40-ITGA2
por: Aloui, Chaker, et al.
Publicado: (2016)

Direct Interaction of CD40 on Tumor Cells with CD40L on T Cells Increases the Proliferation of Tumor Cells by Enhancing TGF-β Production and Th17 Differentiation
por: Kim, Hyemin, et al.
Publicado: (2015)

CD40-directed scFv-TRAIL fusion proteins induce CD40-restricted tumor cell death and activate dendritic cells
por: El-Mesery, M, et al.
Publicado: (2013)

Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas
por: Coveler, Andrew L, et al.
Publicado: (2023)

Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis
por: Teruel, María, et al.
Publicado: (2012)

The Contribution of CD40/CD40L Axis in Inflammatory Bowel Disease: An Update
por: Senhaji, Nezha, et al.
Publicado: (2015)

The CD40–CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
por: Aarts, Suzanne A. B. M., et al.
Publicado: (2017)

CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation
por: Elmetwali, Taha, et al.
Publicado: (2020)

Downregulation of CD40L–CD40 attenuates seizure susceptibility and severity of seizures
por: Pototskiy, Esther, et al.
Publicado: (2021)

CD40/CD40L expression and its prognostic value in cervical cancer
por: Grazia, G.A., et al.
Publicado: (2023)

RNA aptamers with specific binding affinity to CD40 (CD40Apt) represents a promising antagonist of the CD40-CD40L signaling for thyroid-associated ophthalmopathy (TAO) treatment in mouse
por: Chen, Yizhi, et al.
Publicado: (2023)

Understanding the influence of the tumor microenvironment on macrophage responses to CD40 agonists
por: Luheshi, Nadia, et al.
Publicado: (2014)

Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy
por: Kashyap, Abhishek S., et al.
Publicado: (2020)

Humanized CD36 (hCD36) mouse model supports the preclinical evaluation of therapeutic candidates targeting CD36
por: Xie, Xiulong, et al.
Publicado: (2023)

CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_l0kkckgjp0cr334h9qnvjn6h8g